A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.

Precigen had sought accelerated approval for Papzimeos, but the FDA opted to grant it full approval after reviewing data from a Phase I/II trial.

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

NEW YORK – Immunotherapy developer Xilio Therapeutics will showcase new masked T-cell engagers in its clinical pipeline over the next two years, the company said this week while announcing second ...

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.